{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:12:21Z","timestamp":1769152341831,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00415-022-11303-8","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T10:02:52Z","timestamp":1659175372000},"page":"6193-6201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-5192","authenticated-orcid":false,"given":"Alon","family":"Doron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Piura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifat","family":"Vigiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Regev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahum","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-7900","authenticated-orcid":false,"given":"Arnon","family":"Karni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"11303_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41577-021-00531-0","volume":"21","author":"S Shilo","year":"2021","unstructured":"Shilo S, Rossman H, Segal E (2021) Signals of hope: gauging the impact of a rapid national vaccination campaign. Nat Rev Immunol 21:198\u2013199. https:\/\/doi.org\/10.1038\/s41577-021-00531-0","journal-title":"Nat Rev Immunol"},{"key":"11303_CR2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385:1078\u20131090. https:\/\/doi.org\/10.1056\/NEJMoa2110475","journal-title":"N Engl J Med"},{"key":"11303_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050435","author":"A Watad","year":"2021","unstructured":"Watad A, De Marco G, Mahajna H et al (2021) Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines9050435","journal-title":"Vaccines (Basel)"},{"key":"11303_CR4","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","volume":"386","author":"YM Bar-On","year":"2022","unstructured":"Bar-On YM, Goldberg Y, Mandel M et al (2022) Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med 386:1712\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2201570","journal-title":"N Engl J Med"},{"key":"11303_CR5","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","volume":"386","author":"SA Madhi","year":"2022","unstructured":"Madhi SA, Kwatra G, Myers JE et al (2022) Population immunity and covid-19 severity with omicron variant in South Africa. N Engl J Med 386:1314\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa2119658","journal-title":"N Engl J Med"},{"key":"11303_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069761","volume":"376","author":"AS Lauring","year":"2022","unstructured":"Lauring AS, Tenforde MW, Chappell JD et al (2022) Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 376:e069761. https:\/\/doi.org\/10.1136\/bmj-2021-069761","journal-title":"BMJ"},{"key":"11303_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"11303_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"11303_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0032-1329200","volume":"32","author":"NJ Silvestri","year":"2012","unstructured":"Silvestri NJ, Wolfe GI (2012) Myasthenia gravis. Semin Neurol 32:215\u2013226. https:\/\/doi.org\/10.1055\/s-0032-1329200","journal-title":"Semin Neurol"},{"key":"11303_CR10","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatr 48:1246\u20131252. https:\/\/doi.org\/10.1136\/jnnp.48.12.1246","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"11303_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/ene.15147","volume":"29","author":"LD Kaulen","year":"2022","unstructured":"Kaulen LD, Doubrovinskaia S, Mooshage C et al (2022) Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol 29:555\u2013563. https:\/\/doi.org\/10.1111\/ene.15147","journal-title":"Eur J Neurol"},{"key":"11303_CR12","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1007\/s00415-020-10263-1","volume":"268","author":"S Sriwastava","year":"2021","unstructured":"Sriwastava S, Tandon M, Kataria S et al (2021) New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol 268:2690\u20132696. https:\/\/doi.org\/10.1007\/s00415-020-10263-1","journal-title":"J Neurol"},{"key":"11303_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s13760-021-01662-w","volume":"121","author":"S \u017dupani\u0107","year":"2021","unstructured":"\u017dupani\u0107 S, Peri\u0107 \u0160itum M, Majdak M et al (2021) Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. Acta Neurol Belg 121:1039\u20131044. https:\/\/doi.org\/10.1007\/s13760-021-01662-w","journal-title":"Acta Neurol Belg"},{"key":"11303_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-200520","volume":"7","author":"SB Ramaswamy","year":"2020","unstructured":"Ramaswamy SB, Govindarajan R (2020) COVID-19 in refractory myasthenia gravis\u2014a case report of successful outcome. J Neuromuscul Dis 7:361\u2013364. https:\/\/doi.org\/10.3233\/JND-200520","journal-title":"J Neuromuscul Dis"},{"key":"11303_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/mus.26918","volume":"62","author":"P Anand","year":"2020","unstructured":"Anand P, Slama MCC, Kaku M et al (2020) COVID-19 in patients with myasthenia gravis. Muscle Nerve 62:254\u2013258. https:\/\/doi.org\/10.1002\/mus.26918","journal-title":"Muscle Nerve"},{"key":"11303_CR16","doi-asserted-by":"publisher","first-page":"215013272110519","DOI":"10.1177\/21501327211051933","volume":"12","author":"A Chavez","year":"2021","unstructured":"Chavez A, Pougnier C (2021) A case of COVID-19 vaccine associated new diagnosis myasthenia gravis. J Prim Care Community Health 12:21501327211051932. https:\/\/doi.org\/10.1177\/21501327211051933","journal-title":"J Prim Care Community Health"},{"key":"11303_CR17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15581","volume":"13","author":"AR Tagliaferri","year":"2021","unstructured":"Tagliaferri AR, Narvaneni S, Azzam MH, Grist W (2021) A case of COVID-19 vaccine causing a myasthenia gravis crisis. Cureus 13:e15581. https:\/\/doi.org\/10.7759\/cureus.15581","journal-title":"Cureus"},{"key":"11303_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101112","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Tang Y, Li C et al (2021) COVID-19 vaccination in patients with myasthenia gravis: a single-center case series. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines9101112","journal-title":"Vaccines (Basel)"},{"key":"11303_CR19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23251","volume":"14","author":"KJ Sonigra","year":"2022","unstructured":"Sonigra KJ, Sarna K, Vaghela VP, Guthua S (2022) An interesting case of fatal myasthenic crisis probably induced by the COVID-19 vaccine. Cureus 14:e23251. https:\/\/doi.org\/10.7759\/cureus.23251","journal-title":"Cureus"},{"key":"11303_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11140-9","author":"G Sansone","year":"2022","unstructured":"Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol. https:\/\/doi.org\/10.1007\/s00415-022-11140-9","journal-title":"J Neurol"},{"key":"11303_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733418","volume":"12","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Zhou R, Yang H, Yang H (2021) To be or not to be vaccinated: that is a question in myasthenia gravis. Front Immunol 12:733418. https:\/\/doi.org\/10.3389\/fimmu.2021.733418","journal-title":"Front Immunol"},{"key":"11303_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.01.013","author":"I Lotan","year":"2022","unstructured":"Lotan I, Hellmann MA, Friedman Y et al (2022) Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis. Neuromuscul Disord. https:\/\/doi.org\/10.1016\/j.nmd.2022.01.013","journal-title":"Neuromuscul Disord"},{"key":"11303_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15348","author":"A Farina","year":"2022","unstructured":"Farina A, Falso S, Cornacchini S et al (2022) Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15348","journal-title":"Eur J Neurol"},{"key":"11303_CR24","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","volume":"265","author":"NE Gilhus","year":"2018","unstructured":"Gilhus NE, Romi F, Hong Y, Skeie GO (2018) Myasthenia gravis and infectious disease. J Neurol 265:1251\u20131258. https:\/\/doi.org\/10.1007\/s00415-018-8751-9","journal-title":"J Neurol"},{"key":"11303_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12883-022-02564-x","volume":"22","author":"LP Digala","year":"2022","unstructured":"Digala LP, Prasanna S, Rao P et al (2022) Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World DataTM study. BMC Neurol 22:38. https:\/\/doi.org\/10.1186\/s12883-022-02564-x","journal-title":"BMC Neurol"},{"key":"11303_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27497","author":"O Gungor Tuncer","year":"2022","unstructured":"Gungor Tuncer O, Deymeer F (2022) Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.27497","journal-title":"Muscle Nerve"},{"key":"11303_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116888","volume":"414","author":"F Delly","year":"2020","unstructured":"Delly F, Syed MJ, Lisak RP, Zutshi D (2020) Myasthenic crisis in COVID-19. J Neurol Sci 414:116888. https:\/\/doi.org\/10.1016\/j.jns.2020.116888","journal-title":"J Neurol Sci"},{"key":"11303_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/ard.2010.144741","volume":"70","author":"WG Dixon","year":"2011","unstructured":"Dixon WG, Kezouh A, Bernatsky S, Suissa S (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 70:956\u2013960. https:\/\/doi.org\/10.1136\/ard.2010.144741","journal-title":"Ann Rheum Dis"},{"key":"11303_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/mus.22077","volume":"43","author":"E Auriel","year":"2011","unstructured":"Auriel E, Regev K, Dori A, Karni A (2011) Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve 43:893\u2013894. https:\/\/doi.org\/10.1002\/mus.22077","journal-title":"Muscle Nerve"},{"key":"11303_CR30","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP et al (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"key":"11303_CR31","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1016\/j.vaccine.2007.03.053","volume":"25","author":"N Souayah","year":"2007","unstructured":"Souayah N, Nasar A, Suri MFK, Qureshi AI (2007) Guillain-Barre syndrome after vaccination in United States a report from the CDC\/FDA Vaccine Adverse Event Reporting System. Vaccine 25:5253\u20135255. https:\/\/doi.org\/10.1016\/j.vaccine.2007.03.053","journal-title":"Vaccine"},{"key":"11303_CR32","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW, Falsey AR et al (2020) Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med 383:2439\u20132450. https:\/\/doi.org\/10.1056\/NEJMoa2027906","journal-title":"N Engl J Med"},{"key":"11303_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100253","volume":"12","author":"M Amanzio","year":"2022","unstructured":"Amanzio M, Mitsikostas DD, Giovannelli F et al (2022) Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: a systematic review. Lancet Reg Health Eur 12:100253. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100253","journal-title":"Lancet Reg Health Eur"},{"key":"11303_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21440","volume":"40","author":"L Zinman","year":"2009","unstructured":"Zinman L, Thoma J, Kwong JC et al (2009) Safety of influenza vaccination in patients with myasthenia gravis: a population-based study. Muscle Nerve 40:947\u2013951. https:\/\/doi.org\/10.1002\/mus.21440","journal-title":"Muscle Nerve"},{"key":"11303_CR35","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/idr13040084","volume":"13","author":"R Shekhar","year":"2021","unstructured":"Shekhar R, Garg I, Pal S et al (2021) COVID-19 vaccine booster: to boost or not to boost. Infect Dis Rep 13:924\u2013929. https:\/\/doi.org\/10.3390\/idr13040084","journal-title":"Infect Dis Rep"},{"key":"11303_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jmv.27334","volume":"94","author":"L Yue","year":"2022","unstructured":"Yue L, Xie T, Yang T et al (2022) A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine. J Med Virol 94:35\u201338. https:\/\/doi.org\/10.1002\/jmv.27334","journal-title":"J Med Virol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11303-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T12:05:25Z","timestamp":1667131525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11303-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["11303"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11303-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}